

## **AeroSafe Global Announces Four Executive Appointments**

*Additions deepen expertise for future growth amid demand for COVID-19 vaccine distribution solutions*

**ROCHESTER, N.Y. (December 14, 2020)** – AeroSafe Global, leader of cold chain technologies and solutions, announced today that it has appointed four senior executives; Ms. Robin Hoke as Member to the Board of Directors, Ms. Anjana Narain as Chief Commercial Officer and AeroSafe Global Advisory Board Member, Ms. Severine Vercruysse as Vice President of Marketing and Mr. Scott Whyte as Chief Digital Officer. These senior executives possess significant commercial and digital expertise, as well as extensive strategic leadership experience in the biopharmaceutical industry. This prestigious group of professionals will help lead AeroSafe Global as it prepares for dramatic growth related to the safe, global distribution of COVID-19 vaccines.

“The global scale and urgency around this pandemic will require arguably the largest cold chain distribution system ever built,” said Jay McHarg, CEO of AeroSafe Global. “We are confident that the addition of these outstanding individuals to our executive leadership team will support our continued growth and evolution as we prepare to serve as reliable partners for the benefit of patients worldwide.”

Ms. Hoke is President and CEO of Leiters, an FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. Hoke brings nearly three decades of relevant experience to AeroSafe Global, previously serving on the boards of Oncobiologics, Inc. and Ricerca Biosciences, as well as holding senior leadership roles at Cardinal Health and Abbott Laboratories. “AeroSafe pioneered the development of cold-chain-as-a-service with its specialized containers for shipping and storing ultra-temperature-sensitive vaccines, and I’m proud to join this organization at a time when the world needs cold chain innovation most.”

Ms. Narain is Chief Commercial Officer at AeroSafe Global and a seasoned leader in vaccines and biopharmaceuticals. Anjana has a proven track record of strong leadership that has delivered industry-leading performance and sustainable growth. She has nearly 30 years of experience with major pharmaceutical companies, most recently as Executive Vice President and General Manager at Seqirus, one of the largest influenza vaccine providers in the world, in addition to global and U.S. commercial leadership roles at GSK, Merck, and Bayer. “It is mission critical that COVID-19 vaccines reach patients safely and that each dose remains viable. AeroSafe’s solution plays a critical role in global cold chain strategy, and I am honored to support the company in this time of unprecedented growth.”

Ms. Vercruysse is Global Vice President of Marketing at AeroSafe Global. Ms. Vercruysse brings 20 years of Marketing/Sales experience, of which 16 years were with GlaxoSmithKline (GSK) in various roles spanning multiple therapeutic areas and product launches within the EU markets. “I’m very excited to be part of AeroSafe Global’s new chapter of innovation and growth. I’m convinced AeroSafe Global can make a difference to healthcare partners with its innovative packaging technology, unique sustainable re-use model and other customized value-adding services. In the very short term, I look forward to contributing with all our employees to our critical mission of distributing safe and efficient COVID19 vaccines worldwide.”

Mr. Whyte is Chief Digital Officer at AeroSafe Global where he is responsible for driving the company’s innovative digital strategy, partner and customer relationships. Whyte’s experience spans 25 years, most recently as Chief Strategy Officer for ClearDATA, the leading life sciences and health care cloud automation and security company. In addition, Scott served prior senior leadership roles at CommonSpirit Health, Phoenix Children’s Hospital, EY, Siemens Healthcare and Capgemini serving hospitals, health insurers and life sciences companies. “AeroSafe’s digitally-enabled containers offer tremendous value when it comes to optimizing medication integrity, cold chain logistics, sustainability and end-user education, all very necessary for ensuring the safe delivery of COVID-19 vaccines across the world. I am honored to leverage my digital expertise to ease adherence to best practices that will lead to a world free of COVID-19.”

AeroSafe Global boasts an established global footprint groomed over the course of many years serving biopharmaceutical distribution demands around the world. The company’s new executive appointments strengthen its depth of healthcare industry expertise and leadership, reinforcing its position as ready partners in championing COVID-19 vaccine accessibility worldwide.

### **About AeroSafe Global**

AeroSafe Global pioneered cold-chain-as-a-service (CCaaS), which includes proprietary technologies and turn-key solutions that biopharmaceutical manufacturers rely on for shipping temperature-sensitive products. AeroSafe

Global has an established footprint and history of over 15 years spent addressing supply chain distribution demands around the world. The company's global network of service centers recovers, rebuilds and certifies parcel solutions every turn, staying true to its focus on sustainability everywhere. With its patented container technology, digital engagement services, and complementary logistics platform, the company provides simple, reliable, flexible and sustainable cold chain solutions for the biopharmaceutical industry.

For additional information, please visit [www.aerosafeglobal.com](http://www.aerosafeglobal.com).